Sesen Bio Inc

Sesen Bio — Corporate Update (July 2020)

77 slides from Sesen Bio's corporate update, Jul 31, 2020

  1. Slide 1: July 2020 Business Update

    July 2020 Business Update Thomas Cannell DVM, President & CEO For Investor Purposes Only July 31, 2020 NASDAQ: SESN

  2. Slide 2: Forward-Looking Statements

    FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, clinical devel

  3. Slide 3: The Patient Journey

    BLOOD IN URINE See PCP; therapeutic trial of antibiotics prescribed Still see blood in urine See blood in urine; THE PATIENT JOURNEY try different antibiotic Confusion and concern on problem Begin tests REFERRED TO Shock and UROLOGIST st CT Scan emotional Preparing for 1 TURBT struggle cancer treatm

  4. Slide 4: July 2020 Business Update

    JULY 2020 BUSINESS UPDATE • FDA conditional acceptance of Vicineum tradename represents important milestone in commercial readiness in the US • Differentiated MOA enables compelling benefit- risk profile for Vicineum • China partnership with Qilu represents first of 6- 10 anticipated OUS deals • Cle

  5. Slide 5: FDA Conditional Acceptance of Vicineum Tradename

    FDA Conditional Acceptance of Vicineum Tradename Differentiated vs. branded agents in Urology TM 5

  6. Slide 6: Vicineum has a Highly Differentiated Mechanism of Action

    Vicineum has a Highly Differentiated Mechanism of Action Mechanism 1: Mechanism 2: Kills cell directly Activates immune system Vicineum selectively targets EpCAM on T cells recognize neoantigen cancer cells while and kill cancer cells generally leaving healthy cells alone Vicineum causes immunogenic

  7. Slide 7: Vicineum has a Highly Differentiated Clinical Profile

    Vicineum has a Highly Differentiated Clinical Profile Efficacy Data Safety Data 3-month response data Intravesical administration • CIS: 40% complete response rate • Bladder wall serves protective function • Papillary: 71% recurrence-free rate • Preference of FDA* and most Urologists Durability of r

  8. Slide 8: Partnership Opportunity in China: Qilu Pharmaceutical

    Partnership Opportunity in China: Qilu Pharmaceutical Profile • Top 10 Pharmaceutical Company in China with >$3B in annual revenues • Extensive clinical experience • 2nd largest clinical team in Chinese Big Pharma • Focused on biosimilar and innovative drugs, with nearly 40 years of clinical develop

  9. Slide 9: Overview of Qilu License Agreement

    Overview of Qilu License Agreement • Financial terms include significant sources of non-dilutive capital • Upfront payment of $12M in cash • Eligibility to receive up to $23M in regulatory and tech transfer milestones in addition to sales royalties for at least 12 years • Qilu will be the Marketing

  10. Slide 10: There is a Significant Unmet Need in China

    There is a Significant Unmet Need in China Bladder Cancer is the 13th Most >300M Adult Smokers in China5 Common Cancer in China1 • Largest smoking population in the • 1.6-1.7 times the incidence vs. the US2 world • Case fatality rate is 41% vs. 22.5% in • Smoking is the most important risk the US3 f

  11. Slide 11: Building Our Reputation as a Partner of Choice

    Building Our Reputation as a Partner of Choice Feedback Received from Qilu During the Negotiation Process Vicineum is a highly differentiated product that addresses a huge unmet need Highly knowledgeable clinical and manufacturing teams Significant CMC capabilities and experience Strong cultural fit

  12. Slide 12: Highly Reliable, Industry-Standard Manufacturing Process for Vicineum

    Highly Reliable, Industry-Standard Manufacturing Process for Vicineum 2000 L E. coli Production Bioreactor Centrifugation (bulk solids removal) Clarification (MF for fine solids removal and UF/DF for buffer exchange) Cell Bank Shake flask 5 Column Purification DP Fill Finish (7 mL @ 5mg/mL) 1: Q-Sep

  13. Slide 13: Forward-looking Timeline for Vicineum

    Forward-looking Timeline for Vicineum Positive progress in the US and Europe enables a clear regulatory path forward with the following anticipated milestones: Early commercial US BLA completionFDA accepts file FDA approval success 4Q 20 1Q 21 2Q 21 3Q 21 4Q 21 1Q 22 2Q 22 Europe MAA submission HTA/

  14. Slide 14: Sesen Bio OUS Strategy Overview

    Sesen Bio OUS Strategy Overview • Vicineum is a product with potential for registration and reimbursement in multiple developed markets • OUS opportunity for Vicineum is 2-3 times larger than the US • Efficient process to manage strong, engaged relationships with key partners worldwide • Partner wit

  15. Slide 15: Simulation Inputs: US Market

    Simulation Inputs: US Market Estimated patients eligible for branded therapy1 (Annual high-risk NMIBC patients unresponsive to BCG) Lower Bound Upper Bound 7,800 patients 20,400 patients Estimated market share2 (Likely share of branded agents) Lower Bound Upper Bound 20% 75% Approximate year 1 doses

  16. Slide 16: Simulation Inputs: OUS Market

    Simulation Inputs: OUS Market Estimated incidence relative to the US1 Estimated price relative to the US2 (High-risk NMIBC patients unresponsive to BCG) (Anticipated reimbursed price) Lower Bound Upper Bound Lower Bound Upper Bound Europe 1.1 1.3 Europe 0.44 0.84 China 1.6 1.8 China 0.20 0.60 MENA 0

  17. Slide 17: OUS opportunity for Vicineum is 2-3 times larger than the US

    We estimate the OUS opportunity for Vicineum is 2-3 times larger than the US Peak Revenue Opportunity for Vicineum Geography (captures 80% of variance) US $423M - $942M Europe $227M - $556M China $194M - $522M Rest of Asia (incl. Japan) $128M - $330M MENA $74M -$187M Latin America $51M - $150M Canad

  18. Slide 18: Financial Overview

    Financial Overview We have an expected cash runway into 2021 with no outstanding debt • Cash and cash equivalents of approximately $38M as of June 30, 2020* We continue to efficiently strengthen our balance sheet, supporting stage-gated investment in US commercial build • ATM • 1Q 2020: net proceeds

  19. Slide 19: July 2020 Highlights

    JULY 2020 HIGHLIGHTS • FDA conditional acceptance of Vicineum tradename represents important milestone in commercial readiness in the US • Differentiated MOA enables compelling benefit- risk profile for Vicineum • Partnership with Qilu represents first of 6-10 anticipated OUS deals • Clear regulator

  20. Slide 20: Thank You

    THANK YOU

  21. Slide 21: Talented and Experienced Leadership Team Prepared for Commercial Launch

    Talented and Experienced Leadership Team Prepared for Commercial Launch Senior Management Board of Directors Omar Rifi Thomas Cannell, DVM Jay Duker, M.D. Vice President, Business Development President, CEO and Director Chair of the Board of Directors and Alliance Management Monica Forbes Louise Ste

  22. Slide 22: Appendix - Table of Contents

    Appendix - Table of Contents Section Slide number Patient Journey 23-24 Unmet Medical Need 25-28 Dual Mechanism of Action 29-31 Regulatory 32-39 Clinical Data 40-57 Commercial Opportunity 58-71 Manufacturing & Supply Chain 72-75 Intellectual Property 76-77 For Investor Purposes Only 22

  23. Slide 23: Appendix: Patient Journey

    Appendix Patient Journey 23

  24. Slide 24: Patient surveys show bladder cancer experience is among the poorest

    Patient surveys have shown that the experience of those with bladder cancer is one of the poorest1 Key Drivers of Poor Patient Journey in Bladder Cancer vs. Average Experience Among 5 Most Common Cancers2 90 86 80 75 72 68 70 65 60 50 47 40 30 % of Patients Who Had Who Had Experience % ofPatients 20

  25. Slide 25: Appendix: Unmet Medical Need

    Appendix Unmet Medical Need 25

  26. Slide 26: Significant Unmet Medical Need in NMIBC

    Significant Unmet Medical Need in NMIBC ~440,000 Bladder cancer is the 6th most prevalent cancer in the US, of which 75%-85% is NMIBC2,3 new cases each year globally1 Bladder cancer is the most expensive cancer to treat in the US with projected costs of ~$6B by 20204 One of the worst patient experie

  27. Slide 27: Vicineum is cystectomy-sparing

    Our Phase III data suggests Vicineum is cystectomy-sparing by significantly delaying or avoiding cystectomy for patients Your Bladder: An Essential Organ Radical Cystectomy: Life-Altering Surgery Self-controlled storage organ in Often a 10 hour or longer surgery the body In women, removal of the ent

  28. Slide 28: Latest global BCG shortage expected to last through 2020

    Latest global BCG shortage expected to last through 2020 2012 2013 2014 2015 2016 2017 2018 2019 2020 Sanofi suspends production Merck announces shortages Sanofi discontinues all global Merck announces supply of BCG Connaught strain of BCG Tice strain production of BCG constraints of BCG Tice strain

  29. Slide 29: Appendix: Dual Mechanism of Action

    Appendix Dual Mechanism of Action 29

  30. Slide 30: Vicineum is Highly Differentiated and has a Dual Mechanism of Action

    Vicineum is Highly Differentiated and has a Dual Mechanism of Action • Fusion protein consisting of an antibody fragment and a cytotoxic payload • Small size facilitates tumor penetration and greater drug delivery • Selectively targets cancer cells while generally sparing healthy cells • Inhibits pr

  31. Slide 31: High somatic mutation rate in bladder cancer

    The high somatic mutation rate in bladder cancer may lead to a better response to agents such as Vicineum that may stimulate T cell-mediated immune activation driven by neoantigens Adapted from Zahir et al. Nature Medicine, 2017 31

  32. Slide 32: Appendix: Regulatory

    Appendix Regulatory 32

  33. Slide 33: Long-term relationship with the agency shaped our program

    Our long-term relationship with the agency has allowed us to shape our nonclinical and clinical program in alignment with FDA guidance 2018 FDA Guidance Vicineum Clinical Program • Conduct nonclinical studies to assess toxicity in animal models • Conduct nonclinical studies to demonstrate anti-tumor

  34. Slide 34: Strong benefit-risk profile in our Phase III Trial

    Vicineum demonstrates a strong benefit-risk profile in our Phase III Trial Efficacy Surrogate Time to Health Endpoints Cystectomy Outcomes Benefit Risk : Safety and Tolerability Selectively targets cancer cells while generally avoiding healthy cells Favorable profile relative to BCG, Valstar, checkp

  35. Slide 35: Initiation of Vicineum BLA submission under Rolling Review

    Initiation of Vicineum BLA submission under Rolling Review on December 6, 2019 Oncology Products Reviewed by FDA 2006 - 2015 Phase Probability of Approval Products at end of Phase I 5% Products at end of Phase II 8% Products at end of Phase III 33% Products with BLA Submission 82% As part of a compr

  36. Slide 36: Significant Progress in 2019

    Significant Progress in 2019 4 Pivotal Face-to-Face Meetings Led to BLA Submission of Clinical/Nonclinical Data May 2019: FDA Accepts CMC Analytical Comparability Plan • No additional clinical trials deemed necessary at this time, subject to final review of comparability data in the BLA June 2019: F

  37. Slide 37: BLA Amendment filed in May 2020

    BLA Amendment filed in May 2020 further supports favorable safety and tolerability profile of Vicineum Module 1 Module 2 Module 3 Module 4 Module 5 General corporate Introduction to summary Drug substance 24 Non-clinical studies List of clinical studies information Quality overall summary • Manufact

  38. Slide 38: Analytical Comparability Outlook

    Analytical Comparability Outlook Clear FDA requirements for the PPQ Campaign • Three manufacturing runs for both drug substance and drug product Considerable in-house manufacturing process expertise from clinical manufacturing • Successfully manufactured 10 drug substance and 12 drug product batches

  39. Slide 39: Positive Interactions with EMA on Regulatory Pathway

    Positive Interactions with EMA on Regulatory Pathway for Vicineum May 7, 2020 CHMP clinical advice for Vicineum: • The nonclinical and clinical pharmacology studies, and safety database are all sufficient to support a MAA submission for Vicineum and no additional clinical trials were requested • The

  40. Slide 40: Appendix: Clinical Data

    Appendix Clinical Data 40

  41. Slide 41: Phase III Trial: Patient Demographics

    Phase III Trial: Patient Demographics COHORT 1 COHORT 2 COHORT 3 CHARACTERISTICS CIS that was refractory or CIS that recurred >6 Papillary tumors (without recurred within 6 months CIS) that recurred within of adequate BCG adequate BCG 6 months of adequate BCG Total patients enrolled 86 7 40 Evaluabl

  42. Slide 42: Compelling Clinical Data Set

    Compelling Clinical Data Set Endpoint How Endpoint is Measured Results Complete Response Rate (CRR) • 40% CRR at 3 months Defined as the proportion of patients who show no evidence of high-risk Primary Endpoint • Lower bound of 95% CI rules out clinically unmeaningful CRR disease, or disease progres

  43. Slide 43: Additional Vicineum Clinical Data

    Additional Vicineum Clinical Data Preliminary Phase II vs. Phase III Complete Response Rate Time Point Phase II Pooled CRR (95% Confidence Interval) Phase III Pooled CRR (95% Confidence Interval) 3-months 40% (26%-56%) 40% (30%-51%) 6-months 27% (15%-42%) 28% (19%-39%) 9-months 18% (8%-32%) 21% (13%

  44. Slide 44: Phase III Trial: Evaluable Patient Data Tables by Cohort

    Phase III Trial: Evaluable Patient Data Tables by Cohort for Carcinoma in situ Cohort 1 (n=82) Complete Response Rate Time Point Evaluable Patients Complete Response Rate (95% Confidence Interval) 3-months n=82 39% (28%-50%) 6-months n=82 26% (17%-36%) 9-months n=82 20% (12%-30%) 12-months n=82 17%

  45. Slide 45: Complete and Partial Response

    Complete and Partial Response: In our Phase II clinical trial, 83% of patients had a complete or partial response 3-Month Response 40% of patients had a complete response Start of Treatment with 43% of patients had a partial response Vicineum 17% of patients had no response *Note: Data are from Phas

  46. Slide 46: Duration of Response

    Duration of Response: 52% of CIS patients who had a complete response at 3 months remained disease-free for a total of 12 months after starting treatment Median Duration of Response is 287 days (95% CI, 154-NE* days) (9.4 months)** 100 KM Estimate 80 X Censored 95% CI 60 52% 39% 40 % of Patients wit

  47. Slide 47: Duration of Response: Probability of remaining cancer-free

    Duration of Response: The longer you have a complete response, the higher the probability of remaining cancer-free Probability of Maintaining Complete Response (CR) for at Least One Additional Year* CR at 12 months 74% CR at 9 months 61% CR at 6 months 56% CR at 3 months 42% Day 0 17% 0% 20% 40% 60%

  48. Slide 48: Duration of Response: More efficacious in CIS patients treated with less BCG

    Duration of Response: Vicineum is generally more efficacious in CIS patients treated with less BCG The BCG shortage may cause a new normal wherein patients receive less BCG 100 Legend: 7-9 BCG instillations 80 X Censored 60 Median 40 20 % ofPatients withComplete Response 0 3 6 9 12 15 18 21 At time

  49. Slide 49: Time to Disease Recurrence

    Time to Disease Recurrence: Time to Disease-Recurrence: 50% of high-risk papillary patients who were treated with Vicineum are disease-free at 1 year Median time to recurrence is 402 days per Kaplan-Meier estimate (13.2 months) 100 Legend: 80 KM Estimate X Censored 95% CI 60 50% 40 37% % ofPatients

  50. Slide 50: Recurrence-free Rate

    Recurrence-free Rate: 42% of high-risk papillary patients remain disease- free after one year Recurrence-free Rate (Papillary patients) Time Point Evaluable Patients RF Rate (95% Confidence Interval) 3-months n=38 71% (54%-85%) 6-months n=38 58% (41%-74%) 9-months n=38 45% (29%-62%) 12-months n=38 4

  51. Slide 51: Highly Differentiated Time-to-Cystectomy Data

    Highly Differentiated Time-to-Cystectomy Data vs. Currently Available Agents 76% of patients are cystectomy-free for 3 years No patient on treatment progressed to metastatic disease 100 Legend: KM Estimate X Censored 80 95% CI 60 Median 40 20 % ofPatients Cystectomy-Free 0 0 3 6 9 12 15 18 21 24 27

  52. Slide 52: Time to Cystectomy: Responders vs Non-responders

    Time to Cystectomy: Responders have an 88% probability of remaining cystectomy-free 3 years after starting treatment The average responder remains cystectomy-free for 1,035 days vs 631 days for non-responders 100 Statistically significant difference for 80 responders vs. non-responders: p = < 0.001

  53. Slide 53: Overall Survival

    Overall Survival 1- and 2-year survival rates of patients on trial are comparable to those of the general population of similar age and gender demographics (predominantly male in their 70s) Survival Estimates Patients on VISTA Trial General Population1 1 year 98% 97% 2 years 96% 94% 1U.S. Social Sec

  54. Slide 54: Safety and Tolerability: Phase II and III consistent

    Safety and Tolerability: Our Phase II and Phase III clinical trials are highly consistent for safety and tolerability Increased dosing and duration of exposure does not appear to lead to an increase in incidence or severity of AEs Phase II Phase III Category Treatment-related serious adverse Patient

  55. Slide 55: Safety and Tolerability: No age-related increase in adverse events

    Safety and Tolerability: No age-related increase in adverse events in our Phase III trial The average patient in the VISTA trial was ~74 years old Adverse Events 10 9.0 Treatment-related Adverse Events 7.9 8 7.5 6 4 3.0 2.1 2 1.6 0 54-69 70-79 80+ (n=40) (n=57) (n=36) Age (years) Note: Data consist

  56. Slide 56: 3-month complete response rate data from different clinical trials

    3-month complete response rate data from different clinical trials Please use caution when drawing comparisons across different clinical trials Vicineum 3-month CRR Keytruda 3-month CRR 60 60 U.S. Patients1 Overall1 Overall3 53% U.S. Patients3 50 51% 50 51% 48% 40 40% 41% 40 41% 32% 31% 30 30% 29% 3

  57. Slide 57: Pipeline of Targeted Therapies

    Pipeline of Targeted Therapies We believe there is strong scientific rationale for Vicineum in combination with checkpoint inhibitors. Vicineum in combination with AstraZeneca’s anti-PD-L1, Imfinzi (durvalumab), is being evaluated in a Phase 1 trial run by the National Cancer Institute. PRODUCT CAND

  58. Slide 58: Appendix: Commercial Opportunity

    Appendix Commercial Opportunity 58

  59. Slide 59: Virtuous Cycle: Physicians, Patients, Payers

    Virtuous Cycle: High possibility that all three key segments are advocates & take action Physicians (Ancillary HCPs) Patients Payers (Caregivers/ Encourage use of Vicineum before RC (Private/ families) public) Advocate for product reimbursement Sources: Sesen Bio internal market research: Patient Jo

  60. Slide 60: Large Global Commercial Opportunity

    Large Global Commercial Opportunity Substantial US opportunity and OUS potential of 2-3 times the US • We have CMO partners capable of reliably meeting that demand Anticipated virtuous cycle of advocacy across physicians, patients/caregivers, and payers to drive rapid uptake and strong growth after

  61. Slide 61: Potential to Provide Continuity of Care for Patients with NMIBC

    Vicineum has the Potential to Provide Continuity of Care for Patients with NMIBC Checkpoint Treatment Protocol BCG Vicineum Inhibitors Treatment at Urology office X Directed by Urologist X Administration by Urology nurse X Bladder infusion via urinary catheter X 2-hour infusion, hold, and rotation X

  62. Slide 62: Market Research Input: Clinical Data from Emerging Treatments

    Market Research Input Clinical Data from Emerging Treatments for NMIBC Vicineum Tecentriq (Phase III Data) (Phase II Data) Characteristics Median Patient Age 73 73 Median # of BCG Instillations 12 12 Efficacy N=89 N=73 • At 3 Months 40% 41% • At 6 Months 28% 28% Safety N=133 N=73 Treatment-Related G

  63. Slide 63: Competitive Scan: June 2020

    Competitive Scan: June 2020 BCG-Unresponsive NMIBC Monotherapies Approved/Pipeline Products Checkpoint Inhibitors: Gene Therapy: Adenovirus Vectors Keytruda Adstiladrin • Approved for NMIBC January 2020 • Missed May PDUFA date • Reimbursed at $175,000/year with minimal payer restrictions • Company h

  64. Slide 64: 1Q 2020 Intent-to-Prescribe Market Research Results

    Appendix 1Q 2020 Intent-to-Prescribe Market Research Results We conducted 30-minute interviews with 34 high- prescribing Urologists to assess their views of the Vicineum profile vs. the Keytruda profile based on available clinical information For investor purposes only 64

  65. Slide 65: Market Research Input: Profile of Emerging Treatments for NMIBC

    Market Research Input Profile of Emerging Treatments for NMIBC VicineumProfile Keytruda Profile Selectively targets and kills bladder cancer cells while Binds to the PD-1 receptor, blocking both PD-L1 and Mechanism of Action sparing healthy cells, while also activating the immune PD-L2 from interact

  66. Slide 66: Market Research Input: Clinical Data from Emerging Treatments

    Market Research Input Clinical Data from Emerging Treatments for NMIBC VicineumProfile Keytruda Profile Efficacy N=89 N=102 Complete Response Rate • At 3 Months 40% (CI: 30-51) 41% (CI: 32-51) • At 12 Months 17% 20% • At 18 Months 11% 13% 76% of patients were cystectomy-free Time to Cystectomy No da

  67. Slide 67: High Prescribing Urologists Prefer Vicineum Profile

    1Q 2020 Market Research Results High Prescribing Urologists Prefer Vicineum Profile Intent-to-Prescribe Key Attributes (Stated share of branded agents)* Extremely 10.0 90% 83% 9.0 8.6 80% 8.2 8.2 8.0 70% 7.0 6.2 60% 6.0 5.8 5.4 5.2 50% 5.0 40% Average Rating Average 4.0 % ofpatients 3.4 30% 3.0 17%

  68. Slide 68: Reasons Urologists Prefer Vicineum Profile

    1Q 2020 Market Research Results Reasons Urologists Prefer Vicineum Profile • Urologists strongly prefer to retain ownership of patient journey – High degree of reluctance to refer to Medical Oncologists – Fear of losing follow-up diagnostics with patient after treatment referral • Urologists perceiv

  69. Slide 69: Highly Concentrated Prescriber Base Allows for Efficient Commercial Model

    Highly Concentrated Highly Concentrated Prescriber Base Allowsfor CommercialEfficient Model 1 AUA AUA the of Urology State Workforce and the UnitedPractice in States. 2017. 2 Health VerityHealth 2019. 1 % of Patients 100% 10% 20% 30% 40% 50% 60% 70% 80% 90% 0% 0 200 400 600 800 1,000 1,200 1,400 ~1,

  70. Slide 70: Caregivers play an influential role at treatment decision points

    At treatment decision points, caregivers often play an influential role Our strategy is to educate and inform caregivers via a wide range of digital and social channels Digital • Paid search • Organic search • Videos • Banners • Website (branded or unbranded) Social • Facebook community groups • Twi

  71. Slide 71: Pricing and Reimbursement

    Pricing and Reimbursement US Benchmarks Price Reference Payer Management Responses (Annual Cost) to Pricing2 100% $200K Anticipated Opdivo1 Keytruda1 competitive Tecentriq1 pricing $150K 50% Proportion of Payers $100K 0% $30 K $60 K $90 K $150 K $50K Unrestricted Coverage PA to Label Key: PA to Tria

  72. Slide 72: Appendix: Manufacturing & Supply Chain

    Appendix Manufacturing & Supply Chain 72

  73. Slide 73: Reliable and Inexpensive Manufacturing Process

    Reliable and Inexpensive Manufacturing Process Vicineum is manufactured using a robust, industry-standard microbial expression system The manufacturing process is highly reliable, reducing the risk of supply shortages The manufacturing process is inexpensive, leading to a relatively low cost-of-good

  74. Slide 74: Experienced Partners for Global Manufacturing and Supply of Vicineum

    We have Experienced Partners for the Global Manufacturing and Supply of Vicineum Licensed for commercial production of 8 approved products 25+ years developing and manufacturing biologics 310+ protein-based therapeutics in development and/or manufacturing Proven track record with FDA and worldwide r

  75. Slide 75: Vicineum Commercial Manufacturing Strategy

    Vicineum Commercial Manufacturing Strategy Clinical Supply Commercial Supply Drug Substance Sesen Fuji (CMO) Drug Product Sesen Baxter (CMO) The analytical comparability plan is comprised of 4 key elements: 1. Analytical Release Testing • Assesses the purity, biological activity and general characte

  76. Slide 76: Appendix: Intellectual Property

    Appendix Intellectual Property 76

  77. Slide 77: Vicineum Patent Life

    Vicineum Patent Life Pending Applications Dosing Strategies for Targeting EpCAM positive bladder cancer. If allowed, Stabilized Chimeric Immunoglobulins would expire in 2036 or later. (April 2020 - July 2020) US: 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 Me

Sesen Bio — Corporate Update (July 2020) on 6ix